Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

6d ago, source:

Tempest Therapeutics got promising results using TPST-1120 + Tecentriq + Avastin for liver cancer and TPST-1495 in ...

Tempest Therapeutics, Inc. (TPST)

7d ago, source: Yahoo Finance

BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

15d ago, source:

Preclinical data presented at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more ...

Tempest Reports Year End 2023 Financial Results and Provides Business Update

1mon ago, source: Business Insider

March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight ...

Tempest Therapeutics moves TPST-1120 into phase 3 trial

20d ago, source: Investing

BRISBANE, Calif. - Tempest Therapeutics, Inc. (NASDAQ: TPST), a clinical-stage biotechnology company, announced today that it is preparing to advance its cancer treatment candidate TPST-1120 to a ...

Tempest Therapeutics Inc TPST

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Update

1mon ago, source: Finanznachrichten

March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight ...

Tempest Therapeutics, Inc. Common Stock (TPST)

28d ago, source: Nasdaq

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Tempest Reports Year End 2023 Financial Results and Provides Business Update

1mon ago, source: Yahoo Finance

BRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...